In a significant development for the field of sleep medicine, Vivos Therapeutics Inc. has released compelling new clinical data regarding its Vida oral appliance. The findings, derived from a single-site study, suggest that a non-pharmacological, device-based approach may offer a transformative solution for patients suffering from moderate to severe chronic insomnia. With a 100% success rate in symptom improvement among participants, the study positions the Vida device as a potential disruptor in a market long dominated by pharmaceutical interventions.
Main Facts: A Paradigm Shift in Insomnia Treatment
The core of the recent announcement centers on a clinical study conducted between 2022 and 2025, which evaluated the efficacy of the Vida oral appliance. The device, which utilizes proprietary Unilateral BiteBlock Technology, was tested on a cohort of 37 adult patients.
The primary metric for success was the Insomnia Severity Index (ISI)—a validated clinical tool used to quantify the nature, severity, and impact of insomnia. According to the data provided by Vivos, the average reduction in ISI scores across the study population was 65%. Most notably, every single participant in the study experienced a quantifiable improvement in their symptoms. By the conclusion of the trial, all 37 patients had transitioned from their baseline states of moderate-to-severe insomnia to either "no clinically significant insomnia" or "subthreshold insomnia" classifications.
Unlike traditional insomnia treatments, which often rely on sedatives, sleep hygiene coaching, or complex cognitive behavioral therapy for insomnia (CBT-I), the Vida appliance offers a physical, nightly intervention. The device is designed to be worn while the patient sleeps, aiming to modulate the autonomic nervous system.
Chronology of the Development
The journey of the Vida appliance is one of strategic acquisition and clinical refinement. The device was originally developed by Advanced Facialdontics as the "Pod" oral appliance. Recognizing the potential for the technology to address broader sleep-disordered breathing and related issues, Vivos Therapeutics acquired the technology in early 2023.
The clinical study, conducted by Dr. Scott Simonetti, spanned three years, allowing for a longitudinal look at how patients responded to the treatment over an average of 3.7 months of nightly use. The study cohort was diverse in age—ranging from 28 to 77 years old—and included 30 females and seven males.
Following the conclusion of the study in 2025, Vivos initiated the process of disseminating the findings. While the data has not yet undergone the formal FDA review process specifically for insomnia—the device is currently cleared as a Class II medical device for the treatment of bruxism and TMD—the company has indicated that they have been advised that the current data set is sufficient for them to move forward with the product’s application in this new space.
Supporting Data and Clinical Methodology
To understand the weight of these results, one must look at the demographics and the methodology employed by Dr. Simonetti. The study focused on individuals with "longstanding" insomnia, a group that typically proves difficult to treat due to the physiological and psychological reinforcements of the disorder.
The average usage period of 3.7 months provided enough data to establish that the benefits were not merely placebo-driven but represented a sustained shift in sleep quality. The fact that 100% of participants showed improvement is a statistically rare outcome in sleep medicine, where patient compliance and individual biological variance often lead to mixed results.
The underlying mechanism, according to the inventor, is the modulation of the autonomic nervous system. Chronic insomnia is frequently characterized by a state of hyperarousal, where the sympathetic nervous system remains active during periods that should be dominated by the parasympathetic nervous system. By stabilizing the jaw and the airway, the Vida appliance appears to assist in lowering this hyperarousal state, allowing the patient to transition into, and remain in, deeper stages of sleep.
Official Responses and Expert Perspectives
R. Kirk Huntsman, the Chairman and CEO of Vivos Therapeutics, expressed strong optimism regarding the findings. In a formal press release, he noted that the results are highly consistent with the company’s internal observations regarding patients with COMISA (Co-morbid Insomnia and Obstructive Sleep Apnea).
"Symptomatic relief comes fast, with no material safety issues, and appears to have lasting effects—all at a reasonable cost," Huntsman stated. He highlighted the strategic importance of this data, noting that the Vida appliance could serve as both a significant new treatment modality and a robust revenue stream for the company as it pivots to address one of the most prevalent health issues globally.
Dr. Scott Simonetti, the lead investigator and inventor of the Unilateral BiteBlock Technology, emphasized the clinical implications for providers. "For patients and providers who are looking for effective, non-pharmacologic options for chronic insomnia, the clinical response we observed… is encouraging," said Dr. Simonetti. He remains confident that as awareness of the device grows, the data will support broader clinical adoption, effectively bridging the gap between dental sleep medicine and general psychiatry/sleep medicine.
Implications for the Future of Sleep Health
The implications of this study are multifaceted, touching on regulatory, financial, and clinical domains.
The COMISA Connection
A critical aspect of the study is the focus on COMISA. Insomnia often acts as a gateway or a co-morbid partner to Obstructive Sleep Apnea (OSA). Research suggests that up to 60% of patients with moderate-to-severe OSA also suffer from insomnia. By addressing the insomnia component, Vivos is positioning itself to treat the "whole patient" rather than just the airway obstruction.
Financial and Insurance Barriers
One of the primary challenges identified in the report is the current state of insurance reimbursement. While the home EEG testing associated with the diagnosis may qualify for insurance coverage, the Vida appliance itself is not typically covered by standard insurance carriers. Vivos estimates a potential revenue of approximately $2,000 per patient, covering the testing and the device. This out-of-pocket model may present an initial barrier to entry for some patients, though the company clearly believes the efficacy of the device will justify the investment for those who have exhausted other options.
Regulatory Trajectory
The status of the Vida appliance is unique. It is currently FDA-cleared for the treatment of TMD (temporomandibular disorders) and bruxism (teeth grinding). Using the device to treat insomnia constitutes an "off-label" or "new use" application. While Vivos has stated they have received advice that their current data is sufficient to proceed, the medical community will likely look for further, peer-reviewed, and perhaps multi-site, randomized controlled trials before fully integrating the device into the standard of care.
A Non-Pharmacological Alternative
The medical community has been under mounting pressure to reduce reliance on sedative-hypnotic drugs for sleep, which often come with side effects ranging from daytime grogginess to complex sleep behaviors and potential dependency. If the Vida appliance can provide a sustainable, drug-free path to restorative sleep, it could fundamentally change the treatment algorithm for chronic insomnia patients.
Conclusion
The findings presented by Vivos Therapeutics represent a compelling intersection of dental technology and sleep medicine. By successfully leveraging the Vida appliance to provide relief to 37 patients with long-term insomnia, the company has provided a compelling proof-of-concept.
As Vivos moves into the next phase of its rollout, the medical industry will be watching closely. If the results from this single-site study can be replicated on a larger, multi-center scale, the Vida appliance could shift the treatment paradigm for millions of people worldwide. While the path to widespread adoption will involve navigating insurance reimbursement landscapes and further regulatory scrutiny, the initial data offers a rare glimmer of hope for a condition that has long frustrated both clinicians and patients alike.
For now, the 65% reduction in ISI scores serves as a significant benchmark—a metric that, if sustained, could make the Vida appliance a staple in the future of sleep health management.
